GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
GT Biopharma, Inc. announces a reverse stock split at a ratio of 1-for-30 to regain compliance with the Minimum Bid Price Requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. The reverse stock split reduces the number of outstanding common stock shares from approximately 41,419,000 shares to approximately 1,380,633 shares. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024, and the Company's common stock will begin trading on a post-split basis at the market open on February 5, 2024 under the symbol 'GTBP'.
The announcement by GT Biopharma, Inc. of a reverse stock split is a strategic move aimed at addressing compliance with Nasdaq's Minimum Bid Price Requirement. This action often indicates that a company is facing delisting pressure due to its stock trading below the required threshold. By consolidating shares, the per-share price is artificially increased, which can help maintain the listing status.
However, the reverse split does not inherently change the company's market capitalization or its fundamental value. It's crucial for investors to understand that while the optics of a higher share price might seem positive, the underlying issues causing the low share price, such as performance concerns or market conditions, may still persist. For long-term stakeholders, the focus should remain on the company's operational progress and the potential of its TriKE® platform in the immuno-oncology space.
GT Biopharma's reverse stock split may have implications for investor perception and stock liquidity. Historically, reverse splits can lead to mixed reactions in the market. Some investors view them as red flags, signaling underlying corporate challenges. Others may interpret the move as a company taking necessary steps to stabilize its stock and attract institutional investors who might avoid stocks under a certain price threshold.
Market liquidity could be affected post-split, as the reduced number of shares may lead to lower trading volumes. This could increase volatility or impact the stock's bid-ask spread. Investors should monitor the stock's performance following the split to assess the market's reception of the move and any changes in trading patterns.
The relevance of GT Biopharma's TriKE® platform within the competitive landscape of immuno-oncology treatments is a critical factor for the company's future. The platform's innovation lies in its potential to harness natural killer cells to target and eliminate cancerous cells. The success of clinical trials and eventual regulatory approval would be pivotal in determining the company's valuation and stock performance.
Investors should consider the company's research and development progress, comparing it with industry benchmarks for similar clinical-stage companies. Any delays or advancements in the TriKE® platform's clinical trials could significantly impact the stock's future trajectory, beyond the immediate effects of the reverse stock split.
02/01/2024 - 11:00 AM
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “GTBP” and will begin trading on a post-split basis at the market open on February 5, 2024. The CUSIP number for the common stock following the reverse stock split will be 36254L 308. The reverse stock split is part of the Company’s plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share for continued listing on The Nasdaq Capital Market.
The reverse stock split was approved by the Company’s stockholders at the Company’s Special Meeting of Stockholders held on December 18, 2023, which authorized the Company to effect the reverse stock split at the discretion of the Company’s Board of Directors within certain parameters approved by stockholders. The Company’s Board subsequently approved the final reverse split ratio of 1-for-30.
The reverse stock split reduces the number of shares of the Company’s outstanding common stock from approximately 41,419,000 shares to approximately 1,380,633 shares, subject to adjustment due to the treatment of fractional shares. Proportionate adjustments will be made to the number of shares underlying, and the exercise prices of, the Company’s outstanding stock options and other equity awards, and to the number of shares of common stock issuable under the Company’s equity incentive plans. There will be no change to the number of authorized shares of common stock or to the par value per share.
Information for GTBP Stockholders
As a result of the reverse stock split, every thirty pre-split shares of common stock outstanding will become one share of common stock. The Company’s transfer agent, Computershare Inc. and its wholly owned subsidiary Computershare Trust Company, N.A. (collectively, “Computershare”) will serve as the exchange agent for the reverse stock split.
Registered stockholders holding pre-split shares of the Company’s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split. Stockholders holding shares of the Company’s common stock in certificate form will receive a transmittal letter with instructions as soon as practicable after the effective date.
No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses).
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® ® ® gtbiopharma.com
Forward Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Examples of forward-looking statements in this release include statements regarding effectuating a 1-for-30 reverse stock split. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Contacts: Investor Relations: cdavis@lifesciadvisors.com
SOURCE GT Biopharma, Inc.
What is the purpose of the reverse stock split announced by GT Biopharma, Inc.?
The purpose of the reverse stock split is to regain compliance with the Minimum Bid Price Requirement of $1.00 per share for continued listing on The Nasdaq Capital Market.
What is the ratio of the reverse stock split?
The reverse stock split will be conducted at a ratio of 1-for-30.
When will the reverse stock split become effective?
The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024.
How will the reverse stock split affect the number of outstanding common stock shares?
The reverse stock split will reduce the number of outstanding common stock shares from approximately 41,419,000 shares to approximately 1,380,633 shares.
What will be the new trading symbol for GT Biopharma, Inc. after the reverse stock split?
The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol 'GTBP' and will begin trading on a post-split basis at the market open on February 5, 2024.
How will the reverse stock split affect stockholders who hold shares in brokerage accounts or in 'street name'?
Stockholders who hold their shares in brokerage accounts or in 'street name' will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular processes, and will not be required to take any action in connection with the reverse stock split.
